Dr. Zakaria Thamri
Dr. Zakaria holds a Doctoral degree in pharmacy from Algeria and a Pharmacovigilance certificate from France.
He started his career in Pharmacovigilance at Roche Pharmaceutical, where he has also served in different roles in Medical Affairs and Products Quality.
Dr. Zakaria joined Boehringer Ingelheim in February 2019 as the Local Pharmacovigilance Manager for the North-West Africa Region and is currently the regional Pharmacovigilance Lead for the IMETA region (India, Middle East, Turkey, and Africa) based in Dubai-UAE.
Dr. Zakaria Thamri
Regional Patient Safety & Pharmacovigilance Lead for India, Middle East, Turkey & Africa
Boehringer Ingelheim
Friday 7 June
Challenges and Opportunities for Pharmacovigilance Partnership with License Partners in the Emerging Markets
In some territories, Marketing Authorization holders do not always have legal entities and dedicated PV teams and they are granting rights to Local suppliers.
While it’s crucial to better understand their partners’ PV systems and the way they are complying with their responsibilities and local requirements, ensuring a good collaboration by supporting the local partners to up-scale their PV systems would be a great fix to ensure the fulfillment of the regulatory requirements and ensure Patients’ Safety.
• Whilst licensing agreements involving medicines are primarily driven by commercial considerations, the successful handling of pharmacovigilance obligations is a critical, but frequently overlooked.
• Proposal of efficient collaboration with license partners by supporting them to up-scale their PV system.
Dr. Zakaria Thamri
Regional Patient Safety & Pharmacovigilance Lead for India, Middle East, Turkey & Africa
Boehringer Ingelheim
Thursday 6 June
Panel Discussion: Navigating the Complexities of Drug Safety And the Digital Age
- Discuss the role of real-world data in pharmacovigilance and its impact on drug safety assessments
- Explore opportunities for leveraging digital health data for proactive adverse event monitoring and patient-reported outcomes
- Outsourcing landscape – Partnership model working – Technology and services
- Examine ethical dilemmas related to pharmacovigilance, including issues of patient privacy, informed consent, and the balance between public health surveillance and individual rights
- Examine how AI and ML technologies are transforming pharmacovigilance processes, including adverse event detection, signal detection, and risk assessment
